1. Home
  2. HE vs BLTE Comparison

HE vs BLTE Comparison

Compare HE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HE
  • BLTE
  • Stock Information
  • Founded
  • HE 1891
  • BLTE 2018
  • Country
  • HE United States
  • BLTE United States
  • Employees
  • HE N/A
  • BLTE N/A
  • Industry
  • HE Electric Utilities: Central
  • BLTE Biotechnology: Pharmaceutical Preparations
  • Sector
  • HE Utilities
  • BLTE Health Care
  • Exchange
  • HE Nasdaq
  • BLTE Nasdaq
  • Market Cap
  • HE 1.9B
  • BLTE 2.1B
  • IPO Year
  • HE N/A
  • BLTE 2022
  • Fundamental
  • Price
  • HE $11.29
  • BLTE $77.01
  • Analyst Decision
  • HE Hold
  • BLTE Strong Buy
  • Analyst Count
  • HE 4
  • BLTE 4
  • Target Price
  • HE $10.94
  • BLTE $96.00
  • AVG Volume (30 Days)
  • HE 1.6M
  • BLTE 64.5K
  • Earning Date
  • HE 11-07-2025
  • BLTE 11-11-2025
  • Dividend Yield
  • HE N/A
  • BLTE N/A
  • EPS Growth
  • HE N/A
  • BLTE N/A
  • EPS
  • HE N/A
  • BLTE N/A
  • Revenue
  • HE $3,122,881,000.00
  • BLTE N/A
  • Revenue This Year
  • HE $12.58
  • BLTE N/A
  • Revenue Next Year
  • HE $2.10
  • BLTE N/A
  • P/E Ratio
  • HE N/A
  • BLTE N/A
  • Revenue Growth
  • HE 2.36
  • BLTE N/A
  • 52 Week Low
  • HE $8.14
  • BLTE $49.00
  • 52 Week High
  • HE $13.41
  • BLTE $86.53
  • Technical
  • Relative Strength Index (RSI)
  • HE 43.81
  • BLTE 70.06
  • Support Level
  • HE $10.92
  • BLTE $70.80
  • Resistance Level
  • HE $11.26
  • BLTE $74.18
  • Average True Range (ATR)
  • HE 0.22
  • BLTE 2.30
  • MACD
  • HE -0.06
  • BLTE 0.71
  • Stochastic Oscillator
  • HE 28.06
  • BLTE 83.82

About HE Hawaiian Electric Industries Inc.

Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Share on Social Networks: